<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Exenatide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Exenatide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Exenatide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9005" href="/d/html/9005.html" rel="external">see "Exenatide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11347" href="/d/html/11347.html" rel="external">see "Exenatide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F59011451"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Glucagon-Like Peptide-1 Receptor Agonists Safety Update</span>
<span class="collapsible-date">January 2024</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor for and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Fupdate-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type&amp;token=miTanb%2Bz8Mpo90N4aa9rnBvzPyMcyGMouSYn352zIq27XyRAnm%2BDWunTXNDIRGRVPdvEcJ4t0dBZwKHPsWODdcKNBqg8p81GHTpH2D6qQhfyYSllM0BIXdmigC6Atf7BXgPxeZTU1rPJai25j9dr%2BiXxmVJc5lhSTyKtYrSUSj8%3D&amp;TOPIC_ID=132373" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F13796080"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of thyroid C-cell tumors (Bydureon):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Exenatide extended release (ER) causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared with controls. It is unknown whether exenatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of exenatide-ER-induced rodent thyroid C-cell tumors has not been determined. </p>
<p style="text-indent:-2em;margin-left:2em;">Exenatide ER is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of exenatide ER and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with exenatide ER.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F595798"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bydureon BCise;</li>
<li>Bydureon [DSC];</li>
<li>Byetta 10 MCG Pen;</li>
<li>Byetta 5 MCG Pen</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868669"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bydureon [DSC];</li>
<li>Byetta 10 MCG Pen [DSC];</li>
<li>Byetta 5 MCG Pen [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1013299"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiabetic Agent, Incretin Mimetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F56042522"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7253bb59-b685-4f43-aa48-4aa83f602807">Diabetes mellitus, type 2; adjunct to diet and exercise</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2; adjunct to diet and exercise:</b> Children ≥10 years and Adolescents: Extended-release injection (Bydureon/Bydureon BCise): SUBQ: 2 mg once weekly without regard to meals.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56042523"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents: Extended-release injection:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥45 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; pharmacokinetic trials in adults report higher exposure; use caution; monitor for hypovolemia.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F56042524"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥10 years and Adolescents: Extended-release injection: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F595906"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9005" href="/d/html/9005.html" rel="external">see "Exenatide: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:0em;margin-left:2em;">
<b>Clinical considerations:</b> May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for select patients, including those in whom initial therapy with lifestyle intervention and metformin failed, <b>or</b> who cannot take metformin. May be preferred when weight loss is desired and/or in patients with an HbA<sub>1c</sub> relatively far from goal (eg, HbA<sub>1c</sub> 9% to 10%) and type 1 diabetes is not likely; use has not been associated with improved or worsened cardiovascular outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2023','lexi-content-ref-28910237','lexi-content-ref-Wexler.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2023','lexi-content-ref-28910237','lexi-content-ref-Wexler.2020'])">Ref</a></span>). Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>SUBQ: </b>Initial: 5 mcg twice daily within 60 minutes prior to morning and evening meals (or before the 2 main meals of the day, ≥6 hours apart); may increase to 10 mcg twice daily after 1 month if needed to achieve glycemic goals.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed dose: </i>Missed dose should be skipped; resume at the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>SUBQ: </b>2 mg once weekly without regard to meals. If changing the day of administration is necessary, allow at least 3 days between 2 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed dose:</i> Missed dose should be administered as soon as possible if the next scheduled dose is due in ≥3 days; resume usual schedule thereafter. If there are &lt;3 days until next scheduled dose, omit the missed dose and resume administration at the next scheduled weekly dose.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<b>
<i>Conversion from immediate release to extended release:</i></b>Initiate weekly administration of exenatide extended release the day after discontinuing exenatide immediate release. <b>Note:</b> May experience increased blood glucose levels for ~2 to 4 weeks after conversion. Pretreatment with exenatide immediate release is not required when initiating exenatide extended release.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990377"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary; use caution with initiation of therapy or when increasing the dose in patients with CrCl 30 to 50 mL/minute; monitor for hypovolemia.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥45 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary; use caution, monitor for hypovolemia.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;45 mL/minute/1.73 m<sup>2</sup>: Use is not recommended per manufacturer's labeling. However, some data have shown similar safety and efficacy in patients with an eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup> compared to those with an eGFR ≥60 mL/minute/1.73 m<sup>2</sup>; use with caution and monitor carefully (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757838','lexi-content-ref-32306296','lexi-content-ref-28910237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757838','lexi-content-ref-32306296','lexi-content-ref-28910237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50987765"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, the need for dosage adjustment is unlikely as hepatic dysfunction is not expected to affect exenatide pharmacokinetics.</p></div>
<div class="block adr drugH1Div" id="F595844"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence rates are reported for monotherapy use.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (extended release: 4% to 11%; immediate release: 1% to 2%), nausea (8% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (antibody titers commonly decrease with continued use, though a small percentage of patients had increased titers; an attenuated glycemic response may be seen with antibody formation)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including abscess at injection site, bruising at injection site, cellulitis at injection site, erythema at injection site, hematoma at injection site, injection-site nodule, injection-site pruritus, tissue necrosis at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (2% to 5%, including severe hypoglycemia)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (2% to 9%), decreased appetite (immediate release: 1% to 2%), dyspepsia (3% to 7%), gallbladder disease (≤2%; including cholecystitis or cholelithiasis), vomiting (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 3%), headache (4% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased heart rate (Robinson 2013), prolongation P-R interval on ECG (Linnebjerg 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, macular eruption, papular rash, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal pain, acute pancreatitis, dysgeusia, eructation, flatulence, hemorrhagic pancreatitis, intestinal obstruction, necrotizing pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, severe hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, exacerbation of renal failure, increased serum creatinine, kidney transplant dysfunction, renal insufficiency</p></div>
<div class="block coi drugH1Div" id="F595820"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Prior serious hypersensitivity to exenatide or any component of the formulation; history of or family history of medullary thyroid carcinoma (exenatide ER only); patients with multiple endocrine neoplasia syndrome type 2 (exenatide ER only); history of drug-induced immune-mediated thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon: End-stage renal disease (ESRD) or severe renal impairment (CrCl &lt;30 mL/minute) including dialysis patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Byetta: Diabetic ketoacidosis, diabetic coma/precoma or type 1 diabetes mellitus; ESRD or severe renal impairment (CrCl &lt;30 mL/minute) including dialysis patients.</p></div>
<div class="block war drugH1Div" id="F595841"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported; discontinue therapy in the event of a hypersensitivity reaction. Serious injection-site reactions (eg, abscess, cellulitis, necrosis), with or without subcutaneous nodules have been reported with use. Isolated cases required surgical intervention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Cases of cholelithiasis and cholecystitis have been reported; gallbladder studies and further clinical assessment are indicated if cholelithiasis is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI symptoms: Most common reactions are GI related; these symptoms may be dose-related and may decrease in frequency/severity with gradual titration and continued use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported; monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain that may radiate to the back, and that may or may not be accompanied by vomiting). Prior to initiating therapy, consider other factors associated with pancreatitis that may be present (eg, hypertriglyceridemia, ethanol abuse, cholelithiasis); it is unknown if exenatide increases the risk for pancreatitis in these patients. If pancreatitis is suspected, discontinue use. Do not resume unless an alternative etiology of pancreatitis is confirmed. Consider alternative antidiabetic therapy in patients with a history of pancreatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Cases of acute renal failure and chronic renal failure exacerbation, including severe cases requiring hemodialysis or kidney transplantation, have been reported. May cause nausea/vomiting/diarrhea with transient hypovolemia that can worsen renal function. Renal dysfunction was usually reversible with appropriate corrective measures, including discontinuation of exenatide. Risk may be increased in patients receiving concomitant medications affecting renal function and/or hydration status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Serious bleeding (may be fatal) from drug-induced immune-mediated thrombocytopenia has been reported. Discontinue use and do not reinitiate therapy if drug-induced thrombocytopenia is suspected; thrombocytopenia may persist for ~10 weeks after discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid tumors: <b>Bydureon: [US Boxed Warning] Thyroid C-cell tumors have developed in animal studies with exenatide ER; it is not known if exenatide ER causes thyroid C-cell tumor, including medullary thyroid carcinoma (MTC) in humans. Patients should be counseled on the potential risk of MTC with the use of exenatide and informed of symptoms of thyroid tumors (eg, neck mass, dysphagia, dyspnea, persistent hoarseness). Use of exenatide ER is contraindicated in patients with a personal or a family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 (MEN2).</b> Consultation with an endocrinologist is recommended in patients who develop elevated calcitonin concentrations or have thyroid nodules detected during imaging studies or physical exam; routine monitoring of serum calcitonin or using thyroid ultrasound for early detection of MTC is of unknown value. Cases of MTC in humans have been reported with the GLP-1 agonist, liraglutide.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">- Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">- Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial glucagon-like peptide-1 (GLP-1) concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 agonists may be redundant to surgery effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Not recommended to be used in patients with gastroparesis or severe GI disease due to frequent GI adverse effects associated with use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with a CrCl &lt;30 mL/minute (exenatide) or &lt;45 mL/minute (exenatide ER) or end-stage renal disease (ESRD). If used in renal transplant recipients, monitor for hypovolemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection-site reactions: Bydureon: Serious injection-site reactions (eg, abscess, cellulitis, necrosis), with or without subcutaneous nodules, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens: According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duplicate therapy: Avoid concurrent use of extended-release (weekly) and immediate-release (daily) exenatide formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Unlike the extended-release formulations (Bydureon, Bydureon BCise), the immediate-release formulation (Byetta) did not show efficacy in the treatment of type 2 diabetes mellitus in pediatric patients 10 to 17 years of age in clinical trials.</p></div>
<div class="block dosfc drugH1Div" id="F28119599"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Bydureon: Extended release formulation</p>
<p style="text-indent:0em;">Byetta: Immediate release formulation</p></div>
<div class="block foc drugH1Div" id="F595910"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bydureon BCise: 2 mg/0.85 mL (0.85 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pen-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bydureon: 2 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Byetta 10 MCG Pen: 10 mcg/0.04 mL (2.4 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Byetta 5 MCG Pen: 5 mcg/0.02 mL (1.2 mL) [contains metacresol]</p></div>
<div class="block geq drugH1Div" id="F595803"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422177"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector</b> (Bydureon BCise Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2MG/0.85ML (per 0.85 mL): $248.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Byetta 10 MCG Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mcg/0.04 mL (per mL): $424.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Byetta 5 MCG Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mcg/0.02 mL (per mL): $849.95</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868670"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bydureon: 2 mg ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Byetta 10 MCG Pen: 10 mcg/0.04 mL ([DSC]) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Byetta 5 MCG Pen: 5 mcg/0.02 mL ([DSC]) [contains metacresol]</p></div>
<div class="block admp drugH1Div" id="F56042526"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: SUBQ: Extended release: Bydureon, Bydureon BCise: Administer via SUBQ injection in the back of the upper arm, thigh, or abdomen; rotate injection sites; may inject in the same body region each week but administer in a different injection site. Do not inject IV or IM. If using concomitantly with insulin, administer as separate injections (do not mix in same syringe); may inject in the same body region as insulin but not adjacent to one another. May administer without regard to meals or time of day. May self-administer with proper training; caregivers should assist pediatric patients. Bydureon and Bydureon BCise are single-dose devices that do not require priming before injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506340','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506340','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon single-dose tray: Administer immediately after reconstitution; the mixture should be white to off-white and cloudy. Do not substitute needles or any other components provided with the single-dose tray.</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon Pen: Allow pen to come to room temperature (wait ≥15 minutes after removal from refrigerator) prior to administration. Hold pen by the end with the orange label and tap firmly against palm of hand to mix; rotate pen every 10 taps (may need to tap 80 times or more to thoroughly mix); suspension should appear opaque and white to off-white and evenly mixed. Administer immediately after mixing; see product labeling for detailed injection instructions. To ensure full dose is delivered, after insertion of needle press, injection button until it clicks and hold for 10 seconds.</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon BCise autoinjector: Allow autoinjector to rest flat and come to room temperature (wait ≥15 minutes after removal from refrigerator) prior to administration. Shake autoinjector vigorously for ≥15 seconds; suspension should appear opaque and white to off-white and evenly mixed and there should no longer be any white along the sides, bottom, or top; may take longer to mix if not stored flat. Administer immediately after mixing. To ensure full dose is delivered, press autoinjector against skin until it clicks and hold for 15 seconds.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Changing day of administration:</i> If changing the day of administration is necessary, allow ≥3 days between 2 doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> Extended-release injection: Missed dose should be administered as soon as possible if the next scheduled dose is due in ≥3 days; resume usual schedule thereafter. If there are &lt;3 days until next scheduled dose, omit the missed dose and resume administration at the next scheduled weekly dose.</p></div>
<div class="block adm drugH1Div" id="F595800"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer via SUBQ injection in the upper arm, thigh, or abdomen; rotate injection sites. If using concomitantly with insulin, administer as separate injections (do not mix); may inject in the same body region as insulin, but not adjacent to one another. Do not inject IV or IM.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Use only if clear, colorless, and free of particulate matter. Administer within 60 minutes prior to morning and evening meal (or prior to the 2 main meals of the day, approximately ≥6 hours apart). Set up each new pen before the first use by priming it. See pen user manual for further details. Dial the dose into the dose window before each administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: May administer without regard to meals or time of day. Bydureon and Bydureon BCise are single-dose devices that <b>do not </b>require priming before injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506340','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506340','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon Pen: Allow pen to come to room temperature (wait at least 15 minutes after removal from refrigerator) prior to administration. Hold pen by the end with the orange label and tap firmly against palm of hand to mix (may need to tap up to 80 times or more to thoroughly mix); suspension should appear opaque and white to off-white and evenly mixed. Administer immediately after mixing. To ensure full dose is delivered, after insertion of needle press injection button until it clicks and hold for 10 seconds.</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon BCise autoinjector: Allow autoinjector to come to room temperature (wait at least 15 minutes after removal from refrigerator) prior to administration. Shake autoinjector vigorously for at least 15 seconds; suspension should appear opaque and white to off-white and evenly mixed. Administer immediately after mixing. To ensure full dose is delivered, press autoinjector against skin until it clicks and hold for 15 seconds.</p></div>
<div class="block hazard drugH1Div" id="F51769424"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the National Institute for Occupational Safety and Health (NIOSH) (2016) list; however, it may meet the criteria for a hazardous drug. Exenatide may cause carcinogenicity, teratogenicity, reproductive toxicity and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Prepared/prefilled syringes may be excluded from some hazardous drug handling requirements; assess risk to determine appropriate containment strategy (USP-NF 2018). Refer to institution-specific handling policies and procedures.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends double gloving and a protective gown during subcutaneous administration from a prepared/prefilled syringe (NIOSH 2016).</p></div>
<div class="block sts drugH1Div" id="F595852"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Bydureon pen: Store under refrigeration at 2°C to 8°C (36°F to 46°F); may be stored at ≤25°C (≤77°F) for up to 4 weeks. Do not freeze (discard if freezing occurs). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Bydureon BCise autoinjector: Store under refrigeration at 2°C to 8°C (36°F to 46°F); if necessary, may store at ≤30°C (≤86°F) for up to 4 weeks. Protect from light. Must be stored flat.</p>
<p style="text-indent:-2em;margin-left:2em;">Byetta: Prior to initial use, store under refrigeration at 2°C to 8°C (36°F to 46°F); after initial use, may store at ≤25°C (≤77°F). Do not freeze (discard if freezing occurs). Protect from light. Pen should be discarded 30 days after initial use.</p></div>
<div class="block meg drugH1Div" id="F10110709"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022200s034lbl.pdf%23page%3D37&amp;token=WZDlHedOZKHpS%2FWNWmJJDV8fsl%2FIkubGvEUoezdsOIfy3Qr9pFHq6Jzh1XqOcvIlTmbr2msOEP7LI0J%2BxJ5qDsdOa%2B6FULPdpwTcDStgZ%2FjFW9kDtUTHvsLjXlSk5DA5&amp;TOPIC_ID=132373" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022200s034lbl.pdf#page=37</a></p>
<p style="text-indent:-2em;margin-left:4em;">Bydureon BCise: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F209210s022lbl.pdf%23page%3D36&amp;token=S7wRu9IVpZ9GZC6s21mLxNZiJQhZcOORAYSvaeiF5f7QzXZBM2UXteBSLugM0mVjCtHJHI6M7INX%2FqDAjrANbb4hYmck058CpmwiGP5yDuGpvoTswFcBXflWzXY2P20Y&amp;TOPIC_ID=132373" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209210s022lbl.pdf#page=36</a></p>
<p style="text-indent:-2em;margin-left:4em;">Byetta: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F021773s046s047lbl.pdf%23page%3D33&amp;token=5z4tXdGPefiZ1%2BZ9%2B2YqrO7XPz5eN9L443yoodc5Vg%2BbghROxee%2F1OCVppsVr7Y85ck5yQ4WJYvn2%2BOULl4psKJSSCrUelz7n4oydCQOEG6TasDfYMOvBaeS1o5K7S48&amp;TOPIC_ID=132373" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021773s046s047lbl.pdf#page=33</a></p></div>
<div class="block usep drugH1Div" id="F53569889"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of type 2 diabetes mellitus (DM) as an adjunct to diet and exercise to improve glycemic control (Extended-release injection [Bydureon, Bydureon BCise]: FDA approved in ages ≥10 years and adults; Immediate-release injection: [Byetta]: FDA approved in adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Exenatide is not indicated for the treatment of type 1 DM. Extended-release exenatide injection is not recommended first line for patients inadequately controlled on diet and exercise.</p></div>
<div class="block cyt drugH1Div" id="F13299306"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F595848"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: May diminish the therapeutic effect of Exenatide. Exenatide may decrease the serum concentration of Hormonal Contraceptives. Management: Administer oral hormonal contraceptives at least one hour prior to exenatide. Monitor blood glucose more frequently when patients treated with exenatide initiate therapy with a hormonal contraceptive. Increases in exenatide doses may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins.  Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides.  Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Exenatide may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56092128"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Glucagon-like peptide-1 (GLP-1) receptor agonists are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F595805"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on in vitro data, exenatide has a low potential to cross the placenta (Hiles 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than exenatide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block mopp drugH1Div" id="F53569805"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Plasma glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors), HbA<sub>1c</sub> (monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change) (ADA 2021); renal function (SCr, BUN); volume/hydration status; signs/symptoms of pancreatitis (amylase, lipase, persistent abdominal pain); triglycerides; signs/symptoms of gallbladder disease; GI symptoms (nausea, vomiting, diarrhea).</p></div>
<div class="block rerp drugH1Div" id="F56042530"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients: Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus or pump regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the "peak."</p>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Preprandial glucose: 70 to 130 mg/dL (ISPAD [DiMeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Postprandial glucose: 90 to 180 mg/dL (ISPAD [DiMeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Bedtime glucose: 80 to 140 mg/dL (ISPAD [DiMeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7%; Target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, or have extensive comorbid conditions (ADA 2020; ISPAD [DiMeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults, nonpregnant (ADA 2021):</p>
<p style="text-indent:-2em;margin-left:4em;">Preprandial glucose: 80 to 130 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">Postprandial glucose: &lt;180 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note:</b> In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is similar to a goal HbA<sub>1c</sub> &lt;7%.</p></div>
<div class="block pha drugH1Div" id="F595853"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exenatide is an analog of the hormone incretin (glucagon-like peptide 1 or GLP-1) which increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake. Exenatide administration results in decreases in hemoglobin A<sub>1c</sub> by approximately 0.5% to 1% (immediate release) or 1.5% to 1.9% (extended release).</p></div>
<div class="block phk drugH1Div" id="F595855"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note:</b> In pediatric patients ≥11 years of age, pharmacokinetic parameters of the extended-release formulation were reported to be similar to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 28.3 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal systemic metabolism; proteolytic degradation may occur following glomerular filtration</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (daily) formulation: 2.4 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (weekly) formulation: ~2 weeks</p>
<p style="text-indent:0em;">Time to peak, plasma: SubQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (daily) formulation: 2.1 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (weekly) formulation: Single dose: Initial period of release of surface-bound exenatide is followed by a gradual release from microspheres with peaks at week 2 and week 6 to 7 respectively; with once-weekly dosing steady state is achieved at 6 to 7 weeks (Bydureon) and 10 weeks (Bydureon BCise).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (majority of dose)</p></div>
<div class="block phksp drugH1Div" id="F51154124"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with mild to moderate renal impairment, exposure to exenatide was increased compared with patients with normal renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038860"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Bydureon bcise | Byetta</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Bydureon bcise | Bydureon Pen | Byetta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Bydureon bcise | Byetta</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Bydureon Pen | Byetta</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Byetta | Exapride</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Baietta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bydureon bcise | Bydureon Pen | Byetta</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Byetta | Byetta long</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bydureon | Byetta</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Byetta</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2018:84-103.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Diabetes Association. 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi:10.2337/dc18-S011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/29222382/pubmed" id="29222382" target="_blank">29222382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31757838">
<a name="31757838"></a>Bethel MA, Mentz RJ, Merrill P, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. <i>Diabetes Care</i>. 2020;43(2):446-452. doi:10.2337/dc19-1065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/31757838/pubmed" id="31757838" target="_blank">31757838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21307137">
<a name="21307137"></a>Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared With Exenatide Twice Daily in Patients With Type 2 Diabetes. <i>J Clin Endocrinol Metab.</i> 2011;96(5):1301-1310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/ 21307137/pubmed" id=" 21307137" target="_blank"> 21307137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bydureon.1">
<a name="Bydureon.1"></a>Bydureon (exenatide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bydureon.4">
<a name="Bydureon.4"></a>Bydureon (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bydureon.8">
<a name="Bydureon.8"></a>Bydureon BCise (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Byetta.1">
<a name="Byetta.1"></a>Byetta (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Byetta.2">
<a name="Byetta.2"></a>Byetta (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Byetta.3">
<a name="Byetta.3"></a>Byetta (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Byetta.4">
<a name="Byetta.4"></a>Byetta (exenatide) injection [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Byetta.5">
<a name="Byetta.5"></a>Byetta (exenatide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114. doi:10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32306296">
<a name="32306296"></a>Guja C, Frías JP, Suchower L, et al. Safety and efficacy of exenatide once weekly in participants with type 2 diabetes and stage 2/3 chronic kidney disease. <i>Diabetes Ther</i>. 2020;11(7):1467-1480. doi:10.1007/s13300-020-00815-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/32306296/pubmed" id="32306296" target="_blank">32306296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14992323">
<a name="14992323"></a>Hiles RA, Bawdon RE, Petrella EM. <i>Ex vivo</i> Human Placental Transfer of the Peptides Pramlintide and Exenatide (Synthetic Exendin-4). <i>Hum Exp Toxicol.</i> 2003;22(12):623-628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/14992323/pubmed" id="14992323" target="_blank">14992323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910237">
<a name="28910237"></a>Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i>. 2017;377(13):1228-1239. doi:10.1056/NEJMoa1612917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/28910237/pubmed" id="28910237" target="_blank">28910237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. <i>J Am Geriatr Soc.</i> 2012. doi:10.1111/jgs.12035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21961484">
<a name="21961484"></a>Linnebjerg H, Seger M, Kothare PA, et al. A thorough QT study to evaluate the effects of single-dose exenatide 10 µg on cardiac repolarization in healthy subjects. <i>Int J Clin Pharmacol Ther</i>. 2011;49(10):594-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/21961484/pubmed" id="21961484" target="_blank">21961484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures -2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23355666">
<a name="23355666"></a>Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. <i>BMJ Open</i>. 2013;3(1):e001986. doi:10.1136/bmjopen-2012-001986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/23355666/pubmed" id="23355666" target="_blank">23355666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30506340">
<a name="30506340"></a>Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. <i>Diabetes Ther</i>. 2019;10(1):5-19. doi:10.1007/s13300-018-0535-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/30506340/pubmed" id="30506340" target="_blank">30506340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/exenatide-pediatric-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.2020">
<a name="Wexler.2020"></a>Wexler DJ. Initial management of blood glucose in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 14, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 132373 Version 50.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
